Trimeris Shifts Focus Away From Fuzeon, Toward Pipeline Diversity
This article was originally published in The Pink Sheet Daily
Executive Summary
Restructuring plan, expected to wrap up by early 2007, will transfer some Fuzeon marketing responsibilities to Roche.
You may also be interested in...
Roche Backs Out Of Collaboration With Trimeris On Next-Generation Fusion Inhibitor
Major management shake-up includes departure of Trimeris CEO.
Roche Backs Out Of Collaboration With Trimeris On Next-Generation Fusion Inhibitor
Major management shake-up includes departure of Trimeris CEO.
Fuzeon Needle-Free Delivery System To Be Resubmitted To FDA In Second Half 2006
Growth for Roche/Trimeris' HIV fusion inhibitor is expected to be driven by the new system, which is currently "approvable" at FDA, and updated HHS treatment guidelines.